University of California, Davis

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  HomeCare Medication Management for People With Dementia

  NCT07872072· HiDO Technologies· Source

• Not yet recruiting

  Restoring Speech With an Intracortical Neuroprosthesis for Post-Stroke Agrammatic Aphasia (BG-Aphasia-02)

  NCT07918768· Leigh R. Hochberg, MD, PhD.· Source

• Not yet recruiting

  Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

  NCT07699107· Phase 4· Nisha Acharya· Source

• Recruiting

  ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

  NCT07021989· Phase 2· Michael Spinner, MD· Source

• Not yet recruiting

  EPX-HTG for Structural Heart Procedures

  NCT07705425· EchoPixel, Inc.· Source

• Recruiting

  Examining Relationships Between Musculoskeletal Function Measurements of Movement Efficiency and Nervous System Function After Chronic Stroke

  NCT07737873· University of California, Davis· Source

• Recruiting

  NORM-HF Pivotal Study

  NCT07574593· Foundry Innovation & Research 1, Limited (FIRE1)· Source

• Recruiting

  Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

  NCT07296744· Supira Medical· Source

• Recruiting

  Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

  NCT07357428· Paradromics· Source

• Recruiting

  ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health

  NCT07505797· iSono Health, Inc.· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

  NCT07108283· Phase 2· Takeda· Source

• Recruiting

  Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

  NCT07142044· Phase 1/2· EicOsis Human Health Inc.· Source

• Recruiting

  Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

  NCT04774536· Phase 1/2· Mark Walters, MD· Source

• Active, not recruiting

  Intralesional Cyclosporine for Alopecia Areata

  NCT07029204· Early phase 1· University of California, Davis· Source

• Recruiting

  Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

  NCT06891755· Apreo Health, Inc.· Source

• Recruiting

  Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

  NCT07100990· Phase 3· Mayo Clinic· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT06533644· Phase 2· Syncromune, Inc.· Source

• Recruiting

  Treatment of Moderate to Severe Refractory Crohn's Disease

  NCT06721962· Phase 1/2· Tr1X, Inc.· Source

• Recruiting

  BBO-11818 in Adult Subjects With KRAS Mutant Cancer

  NCT06917079· Phase 1· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Source

• Active, not recruiting

  A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

  NCT06255028· Phase 1· Century Therapeutics, Inc.· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Recruiting

  Sleep Architecture & Cognition in Focal Epilepsy

  NCT05794295· University of California, Davis· Source

• Recruiting

  Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials

  NCT07674758· Vanderbilt University Medical Center· Source

• Recruiting

  Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

  NCT06574178· University of California, Davis· Source

• Recruiting

  RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

  NCT06359041· Phase 1/2· Cabaletta Bio· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

  NCT06706674· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  The SEQUENCE Trial

  NCT06676956· Northwestern University· Source

• Active, not recruiting

  Device Use Reimagined Through Education And Mentorship

  NCT06546930· University of California, San Francisco· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

  NCT06564974· Catalyst Pharmaceuticals, Inc.· Source

• Recruiting

  Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  NCT06567743· Phase 2· CG Oncology, Inc.· Source

• Recruiting

  A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  NCT06379789· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

  NCT06423430· Abbott Medical Devices· Source

• Recruiting

  A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

  NCT06046495· Phase 1· Avistone Biotechnology Co., Ltd.· Source

• Recruiting

  Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

  NCT06252675· Phase 2· University of California, San Francisco· Source

• Recruiting

  The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health

  NCT06476795· University of California, Davis· Source

• Recruiting

  T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  NCT06343311· Phase 1/2· Estrella Immunopharma, Inc.· Source

• Active, not recruiting

  Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

  NCT06106672· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Recruiting

  Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

  NCT06263426· Johns Hopkins University· Source

• Recruiting

  A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

  NCT06138639· Phase 1/2· Solid Biosciences Inc.· Source

• Active, not recruiting

  Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06290934· Phase 2· Gilead Sciences· Source

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Verastem, Inc.· Source

• Recruiting

  Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  NCT06229210· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Active, not recruiting

  An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

  NCT06129240· Liquidia Technologies, Inc.· Source

• Recruiting

  Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

  NCT06101290· University of California, Davis· Source

• Active, not recruiting

  Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06029972· Phase 2· Gilead Sciences· Source

Showing 50 of 122.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Duchenne muscular dystrophy5 recruiting
• Alzheimer disease4 recruiting
• Lung cancer4 recruiting
• ALS (motor neurone disease)3 recruiting
• Autism3 recruiting
• Head and neck cancer3 recruiting
• Prostate cancer3 recruiting
• Spinal cord injury3 recruiting
• Stroke3 recruiting
• Acute myeloid leukaemia2 recruiting
• Bladder cancer2 recruiting
• Epilepsy2 recruiting
• Heart failure2 recruiting
• HIV2 recruiting
• Mild cognitive impairment2 recruiting
• Myasthenia gravis2 recruiting
• Myelodysplastic syndromes2 recruiting
• Pancreatic cancer2 recruiting
• Type 1 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Bipolar disorder1 recruiting
• Bronchiectasis1 recruiting
• Childhood cancers1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Depression1 recruiting
• Frontotemporal dementia1 recruiting
• Glaucoma1 recruiting
• Haemophilia1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Kidney cancer1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple sclerosis1 recruiting
• Optic neuritis1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Psoriasis1 recruiting
• Sarcoma1 recruiting
• Schizophrenia1 recruiting
• Sickle cell disease1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Recruiting

  MOTION Clinical Trial

  NCT06843980· Moximed· Source

• Terminated

  BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

  NCT06611436· Phase 1/2· Be Biopharma· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Completed

  PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

  NCT06366451· Early phase 1· Presage Biosciences· Source

• Recruiting

  Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

  NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source

• Completed

  Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study

  NCT06125145· University of California, Davis· Source

• Completed

  Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder

  NCT06256367· AbbVie· Source

• Completed

  Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

  NCT05451212· Phase 1· Cabaletta Bio· Source

• Completed

  Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism

  NCT05568927· University of California, San Diego· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Efficacy in iNPH Shunting (PENS) Trial

  NCT05081128· Johns Hopkins University· Source

• Completed

  A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

  NCT05238675· Phase 2· Boehringer Ingelheim· Source

• Completed

  An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

  NCT04950764· Phase 1· Gilead Sciences· Source

• Completed

  A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT05096221· Phase 3· Sarepta Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

  NCT05025787· Phase 2· Maurizio Fava, MD· Source

• Completed

  The Effect of Time-restricted Eating on Liver Metabolism

  NCT04997486· University of California, Davis· Source

• Completed

  A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

  NCT04813926· Bayer· Source

• Completed

  A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

  NCT04504812· Phase 3· Johns Hopkins University· Source

• Completed

  Goals for Reaching Optimal Wellness: GROWell

  NCT04449432· University of California, Davis· Source

• Completed

  Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

  NCT04636229· Phase 3· Organogenesis· Source

• Terminated

  The Effect of Time-Restricted Eating in Cardiometabolic Health

  NCT04484987· University of California, Davis· Source

• Completed

  Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

  NCT04266197· Phase 2· Respira Therapeutics, Inc.· Source

• Completed

  Adalimumab in JIA-associated Uveitis Stopping Trial

  NCT03816397· Phase 4· Nisha Acharya· Source

• Completed

  Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

  NCT04223791· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

  NCT04129931· Phase 2· University of North Carolina, Chapel Hill· Source

• Completed

  Trial of Parkinson's And Zoledronic Acid

  NCT03924414· Phase 4· California Pacific Medical Center Research Institute· Source

• Terminated

  Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

  NCT03590652· Phase 2· University of California, San Diego· Source

• Completed

  Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

  NCT03569293· Phase 3· AbbVie· Source

• Completed

  HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

  NCT03569891· Phase 3· CSL Behring· Source

• Completed

  Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

  NCT03439891· Phase 2· Robin Kate Kelley· Source

• Completed

  Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes

  NCT03333629· Phase 4· Drexel University· Source

• Completed

  Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

  NCT03183245· Phase 3· Humacyte, Inc.· Source

• Completed

  Alzheimer's Disease Neuroimaging Initiative 3

  NCT02854033· University of Southern California· Source

• Completed

  A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

  NCT02932449· Target PharmaSolutions, Inc.· Source

• Completed

  A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

  NCT02815891· Target PharmaSolutions, Inc.· Source

• Completed

  NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients

  NCT04548596· Emory University· Source

• Terminated

  Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

  NCT01247207· Phase 3· PTC Therapeutics· Source

• Recruiting

  Collection of Tissue Samples for Cancer Research

  NCT00900198· National Cancer Institute (NCI)· Source

• Completed

  Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

  NCT01860339· Peggy C Nopoulos· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease219 works · 6 trials
• Obesity133 works · 5 trials
• Heart failure97 works · 3 trials
• Autism56 works · 4 trials
• Osteoarthritis55 works · 6 trials
• Mild cognitive impairment51 works · 3 trials
• Epilepsy44 works · 3 trials
• Primary biliary cholangitis39 works · 4 trials
• Melanoma37 works · 3 trials
• Schizophrenia35 works · 1 trial
• Deep vein thrombosis and pulmonary embolism30 works · 1 trial
• Sarcoma27 works · 2 trials
• Psoriasis26 works · 1 trial
• Pulmonary arterial hypertension22 works · 5 trials
• Duchenne muscular dystrophy18 works · 10 trials
• Bipolar disorder18 works · 2 trials
• Acute lymphoblastic leukaemia18 works · 5 trials
• Spinal cord injury17 works · 3 trials
• Glaucoma16 works · 1 trial
• Hidradenitis suppurativa13 works · 0 trials
• Down syndrome9 works · 0 trials
• Myocarditis9 works · 0 trials
• Gout6 works · 0 trials
• Wilson disease6 works · 1 trial
• Iron deficiency anaemia5 works · 0 trials
• Haemophagocytic lymphohistiocytosis5 works · 0 trials
• Vitiligo5 works · 1 trial
• High blood pressure5 works · 8 trials
• Neurofibromatosis type 14 works · 1 trial
• Essential tremor3 works · 1 trial